WHO WE ARE
ATXA Therapeutics is a clinical-stage pharmaceutical company committed to the advancement of innovative, life-changing treatments for cardiopulmonary diseases. Our research focuses on developing novel antagonists of the Thromboxane Receptor (TP), a key driver of disease within the heart & lungs.
ATXA’s world class team encompasses leading experts in the relevant fields, including scientists, clinicians, and commercial strategists with extensive experience and noted successes in the field of drug development and commercialization.
Driven by innovative research, our aim is to bring accessible, affordable and life-changing treatments to patients with cardiopulmonary diseases, offering them new hope and bettering their lives.
Within a proprietary drug pipeline, ATXA's lead clinical candidate is NTP42, which has platform potential to treat many diseases with high unmet clinical needs & many with blockbuster potential.